Calcium's role in bone pain unclearIn-depth clinical characterization of intravenous iron infusion-induced hypophosphatemic osteomalacia and its resolution.
Calcium's effect isn't isolated
We explored the impact of calcium treatment on bone pain in patients who developed osteomalacia, a condition linked to intravenous iron infusions. Our focus was on a group of 13 patients diagnosed with this condition, who experienced low phosphate levels due to excess fibroblast growth factor 23 (iFGF23) after receiving ferric carboxymaltose (FCM) infusions.
After halting the FCM infusions, these patients were given supportive treatment, which included phosphate, calcium, and active Vitamin D supplementation. We observed improvements in biochemical markers, including increased phosphate levels and reduced pain scores. However, it’s important to note that while calcium was part of the treatment regimen, we could not isolate its specific effects on bone pain from the other supportive measures used.
Ultimately, our findings highlight the importance of monitoring phosphate levels in patients receiving FCM, and stopping these infusions effectively addresses phosphate wasting. Although supportive treatment showed improvements in pain and bone density, the direct impact of calcium on bone pain remains unclear given the combination of treatments involved.
Read More
Promising drug delivery for osteoporosisSynthesis and characterization of novel denosumab/magnesium-based metal organic frameworks nanocomposite prepared by ultrasonic route as drug delivery system for the treatment of osteoporosis.
High relevance due to innovative approach
We developed a novel drug delivery system combining denosumab and magnesium within metal-organic frameworks to target osteoarthritis. The framework showed good potential for loaded drug release, delivering about 72% of denosumab in just 8 hours.
Additionally, it released magnesium ions, which are beneficial for bone formation. Our cytotoxicity tests demonstrated that the system is biocompatible and encourages cell growth over time. While our findings are promising for pain relief linked to osteoporosis, further studies are needed to confirm effectiveness in real-world scenarios.
Read More
We evaluated the effects of pamidronate therapy on children with osteogenesis imperfecta type III. Over the course of treatment, we saw reductions in bone pain, alongside a significant decrease in fracture incidence.
The therapy positively impacted children's daily activities and their overall mobility. Importantly, the treatment was found to be safe, although some patients experienced mild side effects like low calcium levels and a fever. Overall, our findings suggest that bisphosphonate therapy is beneficial for management in these young patients.
Read More
CMT shows potential for pain reliefThe efficacy of choline magnesium trisalicylate (CMT) in the management of metastatic bone pain: a pilot study.
Moderate relevance for clinical practice
We investigated how choline magnesium trisalicylate (CMT) helps alleviate bone pain in patients with metastatic cancer. In a carefully designed study involving 26 participants, we compared CMT against a placebo in a crossover format, measuring pain relief at multiple intervals after dosing.
While we observed a significant reduction in pain just one hour post-treatment with CMT, other comparisons showed improvements that didn't reach statistical significance. This suggested that CMT might assist in managing bone pain, potentially complementing traditional opioids, but overall effectiveness is still under exploration.
Read More